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1. Introduction 
Alzheimer disease (AD) occurs in more than half of 
patients with dementia and is a progressive, degenerative 
neurological disorder (1). The aging population is 
increasing and AD is becoming an increasingly important 
public health problem. Diagnosis of AD is made via a 
combination of clinical history, the results of physical 
and neurological examinations, and neuroimaging and 
laboratory evaluations (2). Neuropathological studies 
suggest that evidence of AD may be present in the brain 
years before the onset of clinical symptoms. Identification 
of AD at the earliest possible time is crucial for optimal 
care and treatment. Therefore, recent studies have focused 
on prodromal AD (3).
Neuroimaging studies are used in the diagnosis 
of dementia. Structural techniques such as computed 
tomography (CT) and magnetic resonance imaging (MRI) 
allow for evaluation of the degree of cerebral atrophy and 
detection of organic causes of dementia. Newer imaging 
techniques such as single photon-emission CT (SPECT), 
positron emission tomography (PET), and perfusion MRI 
are useful to evaluate blood perfusion in AD dementia and 
other dementia groups (4–6). Although these techniques 
have been shown to be valuable, they are often not readily 
available. Perfusion CT (PCT) is another perfusion 
technique that provides rapid and minimally invasive 
assessment of brain perfusion. There are a few studies 
concerning PCT in which dementia has been reported 
(6–8). The goal of the present study was to evaluate the 
usefulness of PCT in assessing brain perfusion in patients 
with AD and to compare it with that of patients without 
dementia.
2. Materials and methods
This study was approved by the Institutional Review Board 
of our university hospital and written informed consent 
was obtained from all subjects. Twenty patients with AD 
were recruited among outpatients visiting the Neurology 
Department of our university. Clinical diagnosis of 
dementia was made according to criteria in the DSM-
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IV and probable AD was determined by excluding other 
dementias in accordance with criteria from the National 
Institute of Neurological and Communicative Disorders 
and Stroke and the AD and Related Disorders Association 
(NINCDS-ADRDA). Patients showed mini-mental state 
examination (MMSE) scores ranging from 14 to 26. The 
MMSE is a standardized, 30-point scale that encompasses 
the following items: orientation to time (5 points), 
orientation to place (5 points), word registration (3 points), 
attention (5 points), word recall (3 points), naming (2 
points), repetition (1 point), following commands (3 
points), reading (1 point), writing (1 point), and pentagon 
copying (1 point). 
The 15 control subjects were healthy individuals with 
no cognitive problems who visited our outpatient clinic 
complaining of headaches and who showed normal 
results on cranial CT. All PCT examinations were done on 
the same 4-detector CT scanner (Sensation 4; Siemens). 
Routine whole-brain CT scans were done before and after 
PCT. A volume of 40 mL of iodinated contrast medium 
(370 mg iodine/mL) was injected via a 14-gauge cannula 
into the antecubital fossa with an automatic injector. The 
injection rate was 4 mL/s and the delay time was 5 s. Forty 
images were obtained from the level of the basal ganglia. 
Slice thickness was 10 mm. All perfusion images were 
postprocessed with PCT analysis software on a workstation 
(Wizard; Siemens). We used the standard convolution 
method for CT perfusion processing. Maximum intensity 
projection perfusion, cerebral blood flow (CBF), cerebral 
blood volume (CBV), and time to peak (TTP) maps 
were created. The region of interest (ROI) was placed 
superior to the sagittal sinus for the assessment of 
perfusion parameters. Relative CBF (rCBF), relative CBV 
(rCBV), and relative TTP (rTTP) values were measured 
symmetrically on maps. All symmetric ROIs were drawn 
by hand on the maximum intensity projection perfusion 
image by a single radiologist (T.Y.) in the bilateral frontal, 
temporal, and occipital cortices, and bilateral lentiform 
nucleus (Figures 1a, 1b, 1c, and 1d). 
We investigated differences in sociodemographic 
features between the groups with the chi-square test for 
categorical variables. Quantitative data obtained from the 
frontal, temporal, and occipital cortices and the lentiform 
nucleus were compared by independent t-test. P < 0.05 was 
considered significant.
3. Results 
Demographic features of the AD patients and control 
subjects are listed in Table 1. There were no significant 
differences between the two groups. Values for rCBF 
are listed in Table 2. Values for the bilateral frontal and 
temporal cortices and bilateral lentiform nucleus were 
significantly lower in the AD group than in the control 
group. 
Values for rCBV are listed in Table 3. Values for the 
bilateral temporal cortex were lower in the AD group 
than in the control group, but these differences were 
not significant. Values obtained from bilateral frontal 
and occipital cortices and lentiform nucleus were not 
significantly different between the AD patients and the 
control group. 
Values for rTTP are listed in Table 4. Values for the 
bilateral frontal, temporal, and occipital lobes, and the 
bilateral lentiform nucleus were significantly higher in the 
AD group than they were in the control group. 
4. Discussion 
CT is the most widely used and oldest imaging modality 
used to evaluate dementia patients. This technique has 
been used to determine reversible causes of dementia 
such as normal pressure hydrocephaly, chronic subdural 
hematoma, mass lesion (i.e. large meningioma), and 
infection. MRI is preferred to identify specific pathologies 
such as atrophy of the medial temporal lobe, hippocampal 
formation, or parahippocampal gyrus, each of which is 
highly predictive of AD (5). 
Magnetic resonance spectroscopy is useful in the 
differential diagnosis and evaluation of progression of 
dementia. Findings of increased myo-inositol to creatine 
levels, increased choline to creatine levels, and decreased 
N-acetylaspartate to creatine levels in the medial temporal 
lobe, and to a lesser degree in the parietal lobe, are markers 
of early stage AD (9).
Volumetric studies evaluate volume loss in limbic 
structures such as the entorhinal cortex, hippocampus, 
amygdala, and hypothalamus. Magnetic resonance 
volumetric analysis may help in distinguishing patients 
with mild cognitive impairments (at risk for proceeding to 
AD) from normal elderly subjects (10).
 Several studies showed cerebral perfusion in AD, 
other dementia groups, and mild cognitive impairment 
patients. Caroli et al (3) showed that parahippocampal 
and inferior temporal hypoperfusion in amnestic mild 
cognitive impairment patients correlated with conversion 
to AD. Some studies have also shown that decreased blood 
flow in the temporoparietal association area is common 
in early stage AD, before cerebral atrophy is detectable. As 
dementia progresses, blood flow decreases in the frontal 
lobe and is relatively well preserved in the pons, primary 
motor cortex, and primary visual cortex of the occipital 
lobe, basal ganglia, and thalamus (7,8,11–20). 
Perfusion MR using dynamic susceptibility contrast-
enhanced MRI can show decreased rCBV in the temporal 
and parietal regions. This finding correlates with the 
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Figure 1. MIP perfusion of pCT at the basal ganglia. A-Frontal, B-Temporal, C-Occipital, D-Lentiform nucleus with freehand drawn 
ROI.
A
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decreased regional CBF observed by PET and SPECT. The 
specificity/sensitivity of 18F-fluorodeoxyglucose PET is 
limited; however, 15O H2O PET or SPECT can be used 
to show perfusion deficits (decreased regional CBF) in the 
hippocampus and temporal and parietal regions (6,8,18–20). 
Although volumetric studies and perfusion MRI, PET, 
and SPECT methods are evolving rapidly, the application of 
these technologies to the clinical investigation of dementia is 
still limited due to availability and cost (16). PCT represents 
an inexpensive, noninvasive, and widely available tool that 
can be applied to measure brain perfusion quantitatively. 
This technique is usually used for evaluating decreased 
perfusion in patients with acute stroke. In addition, it can 
be used to detect brain tumor perfusion and brain perfusion 
with vessel stenosis or vasospasm after trauma. There are 
few reports on the use of PCT in dementia (17,20,21). 
Table 1. Demographic features of the subjects included in the study.
Number Sex Age (years)
Alzheimer disease 20 12 F, 8 M 69.7 ± 5.5
Control subjects 15 11 F, 4 M 67.5 ± 3.5
P-value 0.350 0.091
M: male, F: female.
Table 2. Regional cerebral blood flow values determined by perfusion computed tomography in patients 
with Alzheimer disease and control subjects.
Brain region Alzheimer disease Control subjects P-value
Right frontal cortex 22.3 ± 3.6 27.5 ± 5.7 0.002
Left frontal cortex 21.6 ± 4.1 28.5 ± 6.6 0.001
Right temporal cortex 26.1 ± 4.4 32.0 ± 6.5 0.002
Left temporal cortex 25.7 ± 4.9 32.5 ± 6.1 0.001
Right occipital cortex 26.6 ± 6.5 32.2 ± 8.7 0.956
Left occipital cortex 26.3 ± 6.9 30.2 ± 8.3 0.13
Right lentiform nucleus 24.1 ± 7.5 28.8 ± 5.5 0.03
Left lentiform nucleus 24.6 ± 5.7 28.0 ± 6.1 0.04
Table 3. Regional cerebral blood volume values determined by perfusion computed tomography in 
patients with Alzheimer disease and control subjects.
Brain region Alzheimer disease Control subjects P-value
Right frontal cortex 36.2 ± 8.0 36.4 ± 5.8 0.93
Left frontal cortex 36.3 ± 9.5 37.5 ± 7.1 0.66
Right temporal cortex 40.7 ± 7.7 42.3 ± 6.4 0.49
Left temporal cortex 40.0 ± 9.5 42.6 ± 7.2 0.35
Right occipital cortex 42.1 ± 10.7 41.9 ± 8.5 0.95
Left occipital cortex 42.6 ± 8.4 39.5 ± 8.8 0.29
Right lentiform nucleus 35.2 ± 10.9 37.1 ± 4.2 0.49
Left lentiform nucleus 37.5 ± 7.9 36.5 ± 5.2 0.666
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Zimny et al. (19) performed PCT in 41 patients with AD, 
vascular dementia, or mixed dementia. They showed that 
rCBF and rCBV values in the grey and white matter of the 
bilateral frontal and temporal lobes were lower in patients 
with AD than in patients with vascular dementia; however, 
the authors found no significant difference in rCBF, rCBV, 
or rMTT between patients with AD and patients with 
mixed dementia. However, the authors did not include 
control subjects in that study. Streitparth et al. (18) found 
that the occipital and temporal blood volume decreased 
significantly with an increasing degree of dementia. They 
showed regional hypoperfusion in the frontal, basal ganglia, 
temporal, and occipital region in the group with AD when 
compared with the group of cognitively normal subjects. 
They suggested that PCT may be useful in differentiating 
severity and types of dementia. Zimny et al. (19) suggest 
that analysis of CBF and CBV parameters assessed in PCT 
can be useful in evaluating cognitive impairment in patients 
with dementia and may thus have a role in monitoring 
disease progression or therapeutic response. 
In the present study, we aimed to show usefulness of 
PCT in evaluation of brain perfusion in AD. We included 
15 cognitively normal control subjects and compared their 
perfusion findings with those of the AD group. Our study 
demonstrated cerebral cortical perfusion failure in AD by 
using PCT. We observed decreased rCBF in the frontal and 
temporal cortex and bilateral lentiform nucleus. It should 
be noted that perfusion parameters are relative values that 
depend on software programs and that they are lower than 
physiological values in patient and control groups.
It is known that CBF is the most important parameter 
for ischemia of PCT. It is measured in milliliters of blood 
per 100 g brain tissue/min. CBF values obtained from 
areas of the brain with high energy requirements such 
as the cortical surface or basal ganglia were higher than 
those from the white matter. In the AD group, diffuse 
vascular disturbances affected large brain regions as 
compared with vascular dementia caused by focal vascular 
pathology (20). This result may be related to decreased 
rCBF values. CBF is controlled by changes in the vessel 
diameter (autoregulation) and local calculated rCBF can 
change depending on software program, injection speed, 
and cardiac function. rCBV is defined as the percentage 
of blood vessels in a specific volume of tissue. It is a 
functional parameter and alters with vessel size changes in 
the context of vascular autoregulation. In our study, there 
was no significant difference in rCBV values between the 
two groups. This finding may be explained with vessel 
size changes. We also observed increasing rTTP values 
in bilateral frontal, temporal, and occipital cortex, and 
lentiform nucleus. It is known that mean transit time 
(MTT) and TTP values indicate retarded perfusion, but 
these values are not generally specific. It is also known 
that rTTP values are affected by cardiac problems, but 
our perfusion program did not contain MTT maps. A 
metabolic decrease and hypoperfusion have been reported 
to occur in the posterior parietal cortex, temporal cortex, 
and limbic system in patients with AD. We also found 
hypoperfusion of the temporal lobes in patients with AD, 
as well as a decrease in regional CBF in the frontal lobes 
and bilateral lentiform nucleus, when compared with 
control subjects. Previous studies have shown that mild 
AD is localized more in the cingulate gyrus and that a 
more advanced disease is localized in the temporoparietal 
and frontal cortices (2,14). Tang et al. (22) showed that 
the CBV and CBF of the frontal and temporal lobe, 
hippocampus, and basal ganglia in patients with senile 
dementia were much lower, and the MTT and TTP of 
these areas were higher than those values in the healthy 
group at a low-dose perfusion program. We did not use 
this program in a 4-slice scanner, but our dose values were 
within safe limits. 
Table 4. Time-to-peak values determined by perfusion computed tomography in patients with 
Alzheimer disease and control subjects.
Brain region Alzheimer disease Control subjects P-value
Right frontal cortex 0.97 ± 0.17 s 0.82 ± 0.16 s 0.009
Left frontal cortex 0.92 ± 0.27s 0.77 ± 0.16 s 0.05
Right temporal cortex 1.00 ±0.13 s 0.85 ± 0.15 s 0.004
Left temporal cortex 0.98 ± 0.14 s 0.83 ± 0.12 s 0.002
Right occipital cortex 1.05 ± 0.17 s 0.88 ± 0.14 s 0.003
Left occipital cortex 1.07 ± 0.18 s 0.89. ± 0.14 s 0.002
Right lentiform nucleus 0.93 ± 0.18 s 0.78 ± 0.14 s 0.009
Left lentiform nucleus 0.91 ±0.17 s 0.78. ± 0.14s 0.02
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The patients in the present study had moderate to 
advanced AD; hypoperfusion of the frontal, temporal, and 
basal ganglia regions was observed. One limitation of the 
present study is its limited coverage, which is a disadvantage 
of perfusion CT. Perfusion evaluation at the hippocampal 
level and parietal lobes was not possible in this technique in 
our 4-slice CT scanner.  Second, we could not evaluate the 
relationship between cognitive impairment according to 
the MMSE and according to perfusion parameters. Further 
studies are needed to evaluate the role of PCT in monitoring 
disease progression and therapy response in patients with AD.
In conclusion, PCT is readily available and cost effective 
compared with other perfusion techniques for evaluation 
of brain perfusion in AD patients. rCBF values can be 
more useful in assessing hypoperfusion in the bilateral 
frontal and temporal lobes and the lentiform nucleus. 
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